Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antiviral Therapy of COVID-19
Georgii Gudima, И.А. Кофиади, I.P. Shilovskiy, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8867-8867
Open Access | Times Cited: 24

Showing 24 citing articles:

Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period
Danyi Ao, Xuemei He, Jian Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
A concise review on influenza
Pratibha L. Ayanar, Simran M. Jamadar, Shweta R. Bharati, et al.
International Journal of Research in Medical Sciences (2025) Vol. 13, Iss. 3, pp. 1355-1361
Open Access
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1577-1577
Open Access | Times Cited: 13
SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice
María F. Pavan, Marina Bok, Rafael Betanzos San Juan, et al.
Viruses (2024) Vol. 16, Iss. 2, pp. 185-185
Open Access | Times Cited: 3
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
Life (2024) Vol. 14, Iss. 2, pp. 214-214
Open Access | Times Cited: 3
Impact of Early Antiviral Therapy on SARS-CoV-2 Clearance Time in High-Risk COVID-19 subjects: A Propensity Score Matching Study
Marta Colaneri, Federico Fama, Federico Fassio, et al.
International Journal of Infectious Diseases (2024) Vol. 149, pp. 107265-107265
Closed Access | Times Cited: 1
Prospective Antiviral Effect of Ulva lactuca Aqueous Extract against COVID-19 Infection
Reem Binsuwaidan, Thanaa A. El‐Masry, Mostafa M. El‐Sheekh, et al.
Marine Drugs (2023) Vol. 22, Iss. 1, pp. 30-30
Open Access | Times Cited: 2
Results of clinical trials phases I and II of MIR 19®
Musa Khaitov, Alexandra Nikonova, И.А. Кофиади, et al.
Immunologiya (2023) Vol. 44, Iss. 3, pp. 291-316
Open Access | Times Cited: 2
MIR 19® – world first specific antiviral drug for COVID-19 treatment: development and preclinical studies
Musa Khaitov, Alexandra Nikonova, I.P. Shilovskiy, et al.
Immunologiya (2023) Vol. 44, Iss. 3, pp. 270-290
Open Access | Times Cited: 2
Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods
Mir Saleh Hoseininezhad-Namin, Elaheh Rahimpour, Abolghasem Jouyban
Drug Metabolism Reviews (2024) Vol. 56, Iss. 2, pp. 127-144
Closed Access
The metabolic footprint of Vero E6 cells highlights the key metabolic routes associated with SARS-CoV-2 infection and response to drug combinations
Riccardo Melis, Angela Braca, Daniela Pagnozzi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Research Progress on Sesquiterpene Compounds from Artabotrys Plants of Annonaceae
Yupei Sun, Jianzeng Xin, Yaxi Xu, et al.
Molecules (2024) Vol. 29, Iss. 7, pp. 1648-1648
Open Access
Phase IIa randomized placebo-controlled clinical trial to evaluate the efficacy of bromhexine in combination with standard therapy in the early treatment of COVID-19 in primary care patients
David Ramírez, Romina Rojas, Humberto Fierro, et al.
(2024)
Open Access
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice
Andrea Di Lenarda, Nicola Ferri, Massimiliano Lanzafame, et al.
European Cardiology Review (2024) Vol. 19
Open Access
Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID‐19: A Propensity Score-Matched Analysis
S H Zhang, Songsong Tan, Bin Yang, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 4317-4325
Open Access
IFN-γ derived from activated human CD4+ T cells inhibits the replication of SARS-CoV-2 depending on cell-type and viral strain
Jun Shimizu, Tadahiro Sasaki, Guang Han Ong, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
The application and prospects of antimicrobial peptides in antiviral therapy
Fei Yang, Yunqi Ma
Amino Acids (2024) Vol. 56, Iss. 1
Open Access
State of Knowledge About Thyroid Cancers in the Era of COVID-19—A Narrative Review
Agnieszka Bronowicka-Szydełko, Maciej Rabczyński, I. Dumas, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2829-2829
Open Access
Bisindole Compounds—Synthesis and Medicinal Properties
Maria Marinescu
Antibiotics (2024) Vol. 13, Iss. 12, pp. 1212-1212
Open Access
Exploring nucleoside analogs: key targets in the viral life cycle - advancing strategies against SARS-CoV-2
Roopal Garg, Raveen Kumar, Ritika Srivastava, et al.
Medicinal Chemistry Research (2024) Vol. 33, Iss. 6, pp. 869-884
Closed Access
EFFECTS OF ANTIVIRAL THERAPEUTIC DRUGS FOR SARS-COV-2 ON TREATMENT OUTCOMES AND CLINICAL PARAMETERS
Abdul Bari, Atiqullah Sarwari, Mohammad Hassan, et al.
Eurasian Journal of Ecology (2024) Vol. 79, Iss. 2, pp. 136-146
Open Access
Prolonged SARS‐CoV‐2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report
Ryosuke Kambe, Masamichi Sato, Daisuke Uehara, et al.
Clinical Case Reports (2023) Vol. 11, Iss. 9
Open Access | Times Cited: 1
Features of cell immunity of healthcare workers in the first wave of the SARS-CoV-2 infection pandemic
А. А. Борунова, E. K. Shoua, Е. Н. Захарова, et al.
Immunologiya (2023) Vol. 44, Iss. 6, pp. 776-787
Open Access | Times Cited: 1
Evaluation of the efficacy of different adjuvants in producing murine monoclonal antibodies to the receptor-binding domain of the S-protein of SARS-CoV-2
T. A. Ivashchenko, Yana O. Romanenko, M. A. Marin, et al.
Immunologiya (2023) Vol. 44, Iss. 4, pp. 481-490
Open Access
Page 1

Scroll to top